{"pmid":32464095,"title":"Preying on Public Fears and Anxieties in a Pandemic: Businesses Selling Unproven and Unlicensed \"Stem Cell Treatments\" for COVID-19.","text":["Preying on Public Fears and Anxieties in a Pandemic: Businesses Selling Unproven and Unlicensed \"Stem Cell Treatments\" for COVID-19.","In the midst of a global public health emergency, some businesses are taking advantage of widespread fears by marketing purported stem cell treatments for COVID-19. Such businesses target prospective clients with misleading claims, expose patients to potentially risky stem cell-based products, and undermine efforts to develop evidence-based treatments for COVID-19.","Cell Stem Cell","Turner, Leigh","32464095"],"abstract":["In the midst of a global public health emergency, some businesses are taking advantage of widespread fears by marketing purported stem cell treatments for COVID-19. Such businesses target prospective clients with misleading claims, expose patients to potentially risky stem cell-based products, and undermine efforts to develop evidence-based treatments for COVID-19."],"journal":"Cell Stem Cell","authors":["Turner, Leigh"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32464095","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.stem.2020.05.003","topics":["Treatment"],"weight":1,"_version_":1668079521394327554,"score":9.490897,"similar":[{"pmid":32420049,"pmcid":"PMC7224671","title":"Combating COVID-19 with Mesenchymal Stem Cell therapy.","text":["Combating COVID-19 with Mesenchymal Stem Cell therapy.","The COVID-19 disease is caused by a positive stranded RNA virus called SARS-CoV-2. The virus mainly targets the pulmonary epithelial cells as it's initial site of infection by letting its surface spike protein interact and bind to the host ACE2 receptor. The internalization and gradual replication of the virus results in an exaggerated immune response triggering release of many pro-inflammatory cytokines and chemokines. This immune storm is responsible for multiple health hazards in the host ultimately leading to multiple organ failure. Mesenchymal stem cell therapy offers a promising approach towards mitigating the delirious effects of the infection in the COVID-19 patients. This therapy has shown to reduce the expression of pro-inflammatory cytokines as well as repair of damaged tissues in COVID-19 patients. This review has been organized to put forward the positive aruments and implications in support of mesenchymal stem cell therapy as a necessary approach for treating COVID-19 patients.","Biotechnol Rep (Amst)","Rajarshi, Keshav","Chatterjee, Aroni","Ray, Shashikant","32420049"],"abstract":["The COVID-19 disease is caused by a positive stranded RNA virus called SARS-CoV-2. The virus mainly targets the pulmonary epithelial cells as it's initial site of infection by letting its surface spike protein interact and bind to the host ACE2 receptor. The internalization and gradual replication of the virus results in an exaggerated immune response triggering release of many pro-inflammatory cytokines and chemokines. This immune storm is responsible for multiple health hazards in the host ultimately leading to multiple organ failure. Mesenchymal stem cell therapy offers a promising approach towards mitigating the delirious effects of the infection in the COVID-19 patients. This therapy has shown to reduce the expression of pro-inflammatory cytokines as well as repair of damaged tissues in COVID-19 patients. This review has been organized to put forward the positive aruments and implications in support of mesenchymal stem cell therapy as a necessary approach for treating COVID-19 patients."],"journal":"Biotechnol Rep (Amst)","authors":["Rajarshi, Keshav","Chatterjee, Aroni","Ray, Shashikant"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32420049","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.btre.2020.e00467","keywords":["covid-19","cytokines","immunomodulatory","mesenchymal stem cells","sars-cov-2"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667159284484407296,"score":102.16272},{"pmid":32448377,"title":"Stem cell therapy: a potential approach for treatment of influenza virus and coronavirus-induced acute lung injury.","text":["Stem cell therapy: a potential approach for treatment of influenza virus and coronavirus-induced acute lung injury.","Acute lung injury (ALI), an increasingly devastating human disorder, is characterized by a multitude of lung changes arising from a wide variety of lung injuries. Viral infection is the main cause of morbidity and mortality in ALI and acute respiratory distress syndrome (ARDS) patients. In particular, influenza virus, coronavirus, and other respiratory viruses circulate in nature in various animal species and can cause severe and rapidly spread human infections. Although scientific advancements have allowed for rapid progress to be made to understand the pathogenesis and develop therapeutics after each viral pandemic, few effective methods to treat virus-induced ALI have been described. Recently, stem cell therapy has been widely used in the treatment of various diseases, including ALI. In this review, we detail the present stem cell-based therapeutics for lung injury caused by influenza virus and the outlook for the future state of stem cell therapy to deal with emerging influenza and coronaviruses.","Stem Cell Res Ther","Du, Jiang","Li, Han","Lian, Jie","Zhu, Xinxing","Qiao, Liang","Lin, Juntang","32448377"],"abstract":["Acute lung injury (ALI), an increasingly devastating human disorder, is characterized by a multitude of lung changes arising from a wide variety of lung injuries. Viral infection is the main cause of morbidity and mortality in ALI and acute respiratory distress syndrome (ARDS) patients. In particular, influenza virus, coronavirus, and other respiratory viruses circulate in nature in various animal species and can cause severe and rapidly spread human infections. Although scientific advancements have allowed for rapid progress to be made to understand the pathogenesis and develop therapeutics after each viral pandemic, few effective methods to treat virus-induced ALI have been described. Recently, stem cell therapy has been widely used in the treatment of various diseases, including ALI. In this review, we detail the present stem cell-based therapeutics for lung injury caused by influenza virus and the outlook for the future state of stem cell therapy to deal with emerging influenza and coronaviruses."],"journal":"Stem Cell Res Ther","authors":["Du, Jiang","Li, Han","Lian, Jie","Zhu, Xinxing","Qiao, Liang","Lin, Juntang"],"date":"2020-05-26T11:00:00Z","year":2020,"_id":"32448377","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1186/s13287-020-01699-3","keywords":["acute lung injury","coronaviruses","influenza virus","lung stem/progenitor cells","mesenchymal stem cells","stem cell therapy"],"topics":["Treatment"],"weight":1,"_version_":1667785214064066560,"score":100.30276},{"pmid":32292113,"title":"Stem Cell-Based Therapy for Coronavirus Disease 2019.","text":["Stem Cell-Based Therapy for Coronavirus Disease 2019.","The novel coronavirus disease 2019 (COVID-19) has grown to be a global public-health emergency since patients were first detected in Wuhan, China, in December 2019. As of April 9, 2020, the novel coronavirus (named as SARS-CoV-2 by the International Committee on Taxonomy of Viruses on February 11) has infected 83,251 and 1,484,811 patients in China and the world, respectively. However, we have neither confirmed effective antiviral medications nor vaccines available to deal with this emergency. In this commentary, we offer an alternative promising therapy for COVID-19, that is, mesenchymal stem cell transplantation.","Stem Cells Dev","Zhao, Robert Chunhua","32292113"],"abstract":["The novel coronavirus disease 2019 (COVID-19) has grown to be a global public-health emergency since patients were first detected in Wuhan, China, in December 2019. As of April 9, 2020, the novel coronavirus (named as SARS-CoV-2 by the International Committee on Taxonomy of Viruses on February 11) has infected 83,251 and 1,484,811 patients in China and the world, respectively. However, we have neither confirmed effective antiviral medications nor vaccines available to deal with this emergency. In this commentary, we offer an alternative promising therapy for COVID-19, that is, mesenchymal stem cell transplantation."],"journal":"Stem Cells Dev","authors":["Zhao, Robert Chunhua"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32292113","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1089/scd.2020.0071","keywords":["covid-19","clinical trial","transplantation"],"locations":["Wuhan","China","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1666138494330732545,"score":96.999596},{"pmid":32281052,"title":"Mesenchymal Stem Cell Therapy for COVID-19: Present or Future.","text":["Mesenchymal Stem Cell Therapy for COVID-19: Present or Future.","\"COVID-19\" is the word that certainly isn't forgotten by everybody who lives in the first half of the twenty-first century. COVID-19, as a pandemic, has led many researchers from different biomedical fields to find solutions or treatments to manage the pandemic. However, no standard treatment for this disease has been discovered to date. Probably, preventing the severe acute respiratory infection form of COVID-19 as the most dangerous phase of this disease can be helpful for the treatment and reduction of the death rate. In this regard, mesenchymal stem cells (MSCs)-based immunomodulation treatment has been proposed as a suitable therapeutic approach and several clinical trials have begun. Recently, MSCs according to their immunomodulatory and regenerative properties attract attention in clinical trials. After the intravenous transplantation of MSCs, a significant population of cells accumulates in the lung, which they alongside immunomodulatory effect could protect alveolar epithelial cells, reclaim the pulmonary microenvironment, prevent pulmonary fibrosis, and cure lung dysfunction. Given the uncertainties in this area, we reviewed reported clinical trials and hypotheses to provide useful information to researchers and those interested in stem cell therapy. In this study, we considered this new approach to improve patient's immunological responses to COVID-19 using MSCs and discussed the aspects of this proposed treatment. However, currently, there are no approved MSC-based approaches for the prevention and/or treatment of COVID-19 patients but clinical trials ongoing.","Stem Cell Rev Rep","Golchin, Ali","Seyedjafari, Ehsan","Ardeshirylajimi, Abdolreza","32281052"],"abstract":["\"COVID-19\" is the word that certainly isn't forgotten by everybody who lives in the first half of the twenty-first century. COVID-19, as a pandemic, has led many researchers from different biomedical fields to find solutions or treatments to manage the pandemic. However, no standard treatment for this disease has been discovered to date. Probably, preventing the severe acute respiratory infection form of COVID-19 as the most dangerous phase of this disease can be helpful for the treatment and reduction of the death rate. In this regard, mesenchymal stem cells (MSCs)-based immunomodulation treatment has been proposed as a suitable therapeutic approach and several clinical trials have begun. Recently, MSCs according to their immunomodulatory and regenerative properties attract attention in clinical trials. After the intravenous transplantation of MSCs, a significant population of cells accumulates in the lung, which they alongside immunomodulatory effect could protect alveolar epithelial cells, reclaim the pulmonary microenvironment, prevent pulmonary fibrosis, and cure lung dysfunction. Given the uncertainties in this area, we reviewed reported clinical trials and hypotheses to provide useful information to researchers and those interested in stem cell therapy. In this study, we considered this new approach to improve patient's immunological responses to COVID-19 using MSCs and discussed the aspects of this proposed treatment. However, currently, there are no approved MSC-based approaches for the prevention and/or treatment of COVID-19 patients but clinical trials ongoing."],"journal":"Stem Cell Rev Rep","authors":["Golchin, Ali","Seyedjafari, Ehsan","Ardeshirylajimi, Abdolreza"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32281052","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1007/s12015-020-09973-w","keywords":["covid-19","clinical trials","coronavirus","immunomodulatory","mesenchymal stem cell","stem cell therapy"],"topics":["Treatment"],"weight":1,"_version_":1666138491544666112,"score":96.70939},{"pmid":32423449,"title":"Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients.","text":["Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients.","In late 2019, a novel coronavirus (SARS-CoV-2) emerged in Wuhan, capital city of Hubei province in China. Cases of SARS-CoV-2 infection quickly grew by several thousand per day. Less than 100 days later, the World Health Organization declared that the rapidly spreading viral outbreak had become a global pandemic. Coronavirus disease 2019 (COVID-19) is typically associated with fever and respiratory symptoms. It often progresses to severe respiratory distress and multi-organ failure which carry a high mortality rate. Older patients or those with medical comorbidities are at greater risk for severe disease. Inflammation, pulmonary edema and an over-reactive immune response can lead to hypoxia, respiratory distress and lung damage. Mesenchymal stromal/stem cells (MSCs) possess potent and broad-ranging immunomodulatory activities. Multiple in vivo studies in animal models and ex vivo human lung models have demonstrated the MSC's impressive capacity to inhibit lung damage, reduce inflammation, dampen immune responses and aid with alveolar fluid clearance. Additionally, MSCs produce molecules that are antimicrobial and reduce pain. Upon administration by the intravenous route, the cells travel directly to the lungs where the majority are sequestered, a great benefit for the treatment of pulmonary disease. The in vivo safety of local and intravenous administration of MSCs has been demonstrated in multiple human clinical trials, including studies of acute respiratory distress syndrome (ARDS). Recently, the application of MSCs in the context of ongoing COVID-19 disease and other viral respiratory illnesses has demonstrated reduced patient mortality and, in some cases, improved long-term pulmonary function. Adipose-derived stem cells (ASC), an abundant type of MSC, are proposed as a therapeutic option for the treatment of COVID-19 in order to reduce morbidity and mortality. Additionally, when proven to be safe and effective, ASC treatments may reduce the demand on critical hospital resources. The ongoing COVID-19 outbreak has resulted in significant healthcare and socioeconomic burdens across the globe. There is a desperate need for safe and effective treatments. Cellular based therapies hold great promise for the treatment of COVID-19. This literature summary reviews the scientific rationale and need for clinical studies of adipose-derived stem cells and other types of mesenchymal stem cells in the treatment of patients who suffer with COVID-19.","J Transl Med","Rogers, Christopher J","Harman, Robert J","Bunnell, Bruce A","Schreiber, Martin A","Xiang, Charlie","Wang, Fu-Sheng","Santidrian, Antonio F","Minev, Boris R","32423449"],"abstract":["In late 2019, a novel coronavirus (SARS-CoV-2) emerged in Wuhan, capital city of Hubei province in China. Cases of SARS-CoV-2 infection quickly grew by several thousand per day. Less than 100 days later, the World Health Organization declared that the rapidly spreading viral outbreak had become a global pandemic. Coronavirus disease 2019 (COVID-19) is typically associated with fever and respiratory symptoms. It often progresses to severe respiratory distress and multi-organ failure which carry a high mortality rate. Older patients or those with medical comorbidities are at greater risk for severe disease. Inflammation, pulmonary edema and an over-reactive immune response can lead to hypoxia, respiratory distress and lung damage. Mesenchymal stromal/stem cells (MSCs) possess potent and broad-ranging immunomodulatory activities. Multiple in vivo studies in animal models and ex vivo human lung models have demonstrated the MSC's impressive capacity to inhibit lung damage, reduce inflammation, dampen immune responses and aid with alveolar fluid clearance. Additionally, MSCs produce molecules that are antimicrobial and reduce pain. Upon administration by the intravenous route, the cells travel directly to the lungs where the majority are sequestered, a great benefit for the treatment of pulmonary disease. The in vivo safety of local and intravenous administration of MSCs has been demonstrated in multiple human clinical trials, including studies of acute respiratory distress syndrome (ARDS). Recently, the application of MSCs in the context of ongoing COVID-19 disease and other viral respiratory illnesses has demonstrated reduced patient mortality and, in some cases, improved long-term pulmonary function. Adipose-derived stem cells (ASC), an abundant type of MSC, are proposed as a therapeutic option for the treatment of COVID-19 in order to reduce morbidity and mortality. Additionally, when proven to be safe and effective, ASC treatments may reduce the demand on critical hospital resources. The ongoing COVID-19 outbreak has resulted in significant healthcare and socioeconomic burdens across the globe. There is a desperate need for safe and effective treatments. Cellular based therapies hold great promise for the treatment of COVID-19. This literature summary reviews the scientific rationale and need for clinical studies of adipose-derived stem cells and other types of mesenchymal stem cells in the treatment of patients who suffer with COVID-19."],"journal":"J Transl Med","authors":["Rogers, Christopher J","Harman, Robert J","Bunnell, Bruce A","Schreiber, Martin A","Xiang, Charlie","Wang, Fu-Sheng","Santidrian, Antonio F","Minev, Boris R"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32423449","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1186/s12967-020-02380-2","keywords":["ards","covid-19","mesenchymal stem cells","pneumonia","sars-cov-2"],"locations":["Wuhan","Hubei","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1667352728892866562,"score":91.513084}]}